Biological prognostic and predictive factors in lung cancer

Oncology

Volumn 77, Issue SUPPL. 1, 2010, Pages 90-96

  Rossi, Antonio ^a   Galetta, Domenico ^b   Gridelli, Cesare ^a  

^a S G MOSCATI HOSPITAL   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Chemotherapy; Lung cancer; Non small cell lung cancer; Pemetrexed; Predictive factors; Prognostic factors; Small cell lung cancer; Targeted therapy

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DIHYDROFOLATE REDUCTASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB; GEMCITABINE; K RAS PROTEIN; PACLITAXEL; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; THYMIDYLATE SYNTHASE; EGFR PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG TARGETING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SQUAMOUS CELL CARCINOMA; DRUG ANTAGONISM; GENETICS; LUNG TUMOR; METABOLISM; MUTATION;

HUMANS; LUNG NEOPLASMS; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; THYMIDYLATE SYNTHASE;

EID: 77949911427     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000258500     Document Type: Review

References (42)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
3. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, Piccirillo J: Changing epidemiology of smallcell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24: 4539-4544.
4. Shih C, Chen VJ, Gossetti LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl RA, Moroson BA, Beardsley GP, Kohler W, Ratnam M, Schultz RM: LY231514, a pirrolo[2, 3-d]pyrimidine-based antifolate that inhibits multiple folate requiring enzymes. Cancer Res 1997; 57: 1116-1123.
5. Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, Simms L, Shepherd FA: The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009; 14: 253-263.
6. Shepherd FA, Pereira JR, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132. (Pubitemid 41058344)
7. Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-1537.
8. Pirker R, Rodrigues Pereira J, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373: 1523-1531.
9. Schultz RM, Chen VJ, Bewley JR, Roberts EF, Shih C, Dempsey JA: Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Sem Oncol 1999; 26(suppl 6):68-73.
10. Ceppi P, Volante M, Saviozzi S, Rapa I, Novello S, Cambieri A, Lo Iacono M, Cappia S, Papotti M, Scagliotti GV: Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006; 107: 1589-1596.
11. Scagliotti G, Monica V, Ceppi P, Righi L, Cambieri A, Volante M, Novello S, Cappelletto E, Papotti M: Baseline thymidylate synthetase expression according to histological subtypes of non-small cell lung cancer. J Clin Oncol 2009; 27: 387s, abstract 7521.
12. Belani CP, Brodowicz T, Ciuleanu T, Kim JH, Krzakowski M, Laack E, Wu YL, Peterson P, Krejci K, Zielinski C: Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: a randomized phase III study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2009; 27: 407s, abstract CRA8000.
13. Socinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A, Hong S, Visseren-Grul C, Guba SC, Thatcher N: Phase III study of pemetrexed plus carboplatin (PC) versus etoposide and carboplatin (EC) in chemonaive patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC): interim results. www.asco.org/ASCOv2/Meetings/ Abstracts?&vmview=abst-detail- view&co nfID=55&abstractID=100000 (accessed August 24, 2009).
14. Ceppi P, Volante M, Ferrero A, Righi L, Rapa I, Rosas R, Berruti A, Dogliotti L, Scagliotti GV, Papotti M: Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res 2008; 14: 1059-1064.
15. Rossi A, Ricciardi S, Maione P, de Marinis F, Gridelli C: Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung Cancer 2009, E-pub ahead of print.
16. Wells A: EGF receptor. Int J Biochem Cell Biol 1999; 31: 637-643.
17. Baselga J: Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002; 4: 2-8.
18. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372: 1809-1818.
19. Mok T, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
20. Lee JS, Park K, Kim SW, Lee DH, Kim HT, Han JY, Yun T, Ahn MJ, Ahn JS, Suh C, Lee JS, Han JH, Yu SY, Lee JW, Jo SJ: A randomized phase III study of gefitinib (IRESSA TM ) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. J Thorac Oncol 2009; 4(suppl 1):S283-S284, abstract PRS.4.
21. Harari PM, Allen GW, Bonner JA: Biology of interactions: anti-epidermal growth factor receptor agents. J Clin Oncol 2007; 25: 4057-4065.
22. Cappuzzo F, Ciuleanu T, Stelmah L, Cicenas S, Szczesna A, Juhasz E, Esteban Gonzales E, Molinier O, Klingelschmitt G, Giaccone G: SATURN: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol 2009; 27: 407s, abstract 8001.
23. Socinski MA: What guide decisions about the use of epidermal growth factor receptor antibody or epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer? In: 2009 Educational Book. Alexandria, American Society of Clinical Oncology, 2009, pp 436-443.
24. Cappuzzo F, Ligorio C, Janne PA, Toschi L, Rossi E, Trisolini R, Paioli D, Holmes AJ, Magrini E, Finocchiaro G, Bartolini S, Cancellieri A, Patelli M, Crino L, Varella-Garcia M: Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Aktpositive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol 2007; 25: 2248-2255.
25. Crinò L, Cappuzzo F, Zatloukal P, Reck M, Pesek M, Thompson JC, Ford HE, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Duffield EL, Armour AA, Speake G, Cullen M: Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 2008; 26: 4253-4260.
26. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
27. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Branningan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
28. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rush V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-13311.
29. Shigematsu H, Gazdar AF: Somatic mutations of epidermal growth factor receptor signalling pathway in lung cancers. Int J Cancer 2006; 118: 257-262.
30. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sanchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M: Screening for epidermal growth factor mutations in lung cancer. N Engl J Med 2009; 361: 958-967.
31. Mok TS, To KF, Srimunimimit V, Chao TY, Ichinose Y, Wu YL, Thongprasert S, Duffield E, Rukanzekov Y, Saijo N, Yang CH, Fukuoka M: Clinical outcomes of patients with epidermal growth factor receptor (EGFR) mutations (Mut) in IPASS (IRESSA TM Pan ASia Study). J Thorac Oncol 2009; 4(suppl 1):S351, abstract B9.5.
32. Kobayashi K, Inoue A, Maemondo M, Sugawara S, Isobe H, Oizumi S, Saijo Y, Gemma A, Morita S, Hagiwara K, Nukiwa T: Firstline gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: A phase III study (002) by North East Japan Gefitinib Study Group. J Clin Oncol 2009; 27: 411s, abstract 8016.
33. Gatzemeier U, Paz-Ares L, Rodrigues Pereira J, von Pawel J, Ramlau R, Roh JK, Yu CT, O'Byrne K, Stroh C, Pirker R: Molecular and clinical biomarkers of cetuximab efficacy: data from the phase III FLEX study in nonsmall cell lung cancer (NSCLC). J Thorac Oncol 2009; 4(suppl 1):S324, abstract B2.3.
34. Inoue A, Nukiwa T: Gene mutations in lung cancer: promising predictive factors for the success of molecular therapy. PLoS Med 2005; 2:e13.
35. Riely GJ, Marks J, Pao W: KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009; 6: 201-205.
36. Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M, Haller A, Lothaire P, Meert AP, Noel S, et al: The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005; 92: 131-139.
37. Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou CA, Murray S: Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncology 2008; 9: 962-972.
38. Garassino MC, Borgonovo K, Rossi A, Mancuso A, Martelli O, Tinazzi A, Di Cosimo S, La Verde N, Sburlati P, Bianchi C, Farina G, Torri V: Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Anticancer Res 2009; 29: 2691-2702.
39. Tsao M, Zhu C, Sakurada A, Zhang T, Whitehead M, Kamel-Reid S, Ding K, Seymour L, Shepherd F: An analysis of the prognostic and predictive importance of K-ras mutation status in the National Cancer Institute of Canada Clinical trials Group BR.21 study of erlotinib versus placebo in the treatment of non-small cell lung cancer. J Clin Oncol 2006; 24: 365s, abstract 7005.
40. Brugger W, Triller N, Blasinska-Morawiec M, Curescu S, Salakauskas R, Manikhas G, Mazieres J, Whittom R, Rohr K, Cappuzzo F: Biomarker analyses from the phase III placebo- controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC. J Clin Oncol 2009; 27: 411s, abstract 8020.
41. O'Byrne KJ, Bondarenko I, Barrios C, Eschbach C, Martens U, Hotko Y, Kortsik C, Celik I, Stroh C, Pirker R: Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): data from the FLEX study. J Clin Oncol 2009; 27: 408s, abstract 8007.
42. Gomez-Roca C, Raynaud CM, Penault-Llorca F, Mercier O, Commo F, Morat L, Sabatier L, Dartevelle P, Taranchon E, Besse B, Validire P, Italiano A, Soria JC: Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. J Thorac Oncol 2009; 4: 1212-1220. DOI: 10.1097/ JTO.0b013e3181b44321.